SEC Tracker
Get the app

aTYR PHARMA ATYR

aTyr Pharma reports $18.26 million net loss for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $18.26 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $13.14 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when aTYR PHARMA files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • Net income for the quarter was -$18.3 million.
  • Revenue for the quarter was down 100.0% compared to the same period a year earlier.
  • The financial statements are provided in XBRL format.
  • In its 10-Q for the quarter ended September 30, 2026, aTYR PHARMA INC provided these financial results.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Arvinas ARVN public float $469M, Jun 30, 2025
  2. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
  3. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  4. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  5. Myriad Genetics MYGN public float $494M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.